Halozyme dips as Leerink downgrades on “marginal” Q3 upside

Seeking Alpha · Dulan Lokuwithana · 2026-11-06 16:13 UTC

Halozyme Therapeutics (HALO) stock falls as Leerink Partners downgrades the company noting that its Q3 2026 results only marginally exceeded consensus. Read more here.

Halozyme Therapeutics (HALO) shed more than 13% on Friday as Leerink Partners downgraded the developer of Enhanze drug delivery technology, noting that its recent Q3 2026 results only marginally exceeded Street forecasts.

In addition to “marginal 3Q results upside,” analyst David Risinger

Read the full story at Seeking Alpha · All coverage of this story